FDA Recalls Thyroid Meds Across the US

The Food and Drug Administration has issued a recall for specific lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. These medications are used to treat underactive thyroid and goiter. The agency classified the recall as Class II because the tablets are subpotent, meaning they may not provide the full prescribed dose to the patient.

The recall includes various 10-count blister packs and 100-tablet cartons. The affected dosages range from 25 micrograms to 150 micrograms. Patients who rely on this medication should check their own supply against the specific lot numbers provided on the official FDA website. The expiration dates for the impacted batches fall between July 2026 and January 2027.

Health officials report that any adverse health effects resulting from the lower dose are expected to be temporary and reversible. However, it remains critical for patients to verify their prescriptions immediately. The FDA warns patients not to stop taking the medication abruptly. Anyone matching their pills to the recall list should consult with their doctor or pharmacist to determine the next steps for their treatment plan.

This specific action serves as a reminder for patients to keep track of their medication records and monitor public health notices. By checking the lot numbers on current packaging, users can confirm if their specific prescription is affected by this manufacturing issue. Always speak to a medical professional before making changes to a prescribed health routine.